Latest news
Merck Splits Oncology, Specialty Operations To Brace For Keytruda Patent Loss – Overhauls Leadership To Drive Growth - StocktwitsStocktwits · Fri, 07 Aug 2026 04:30:58 GMTCan Merck (NYSE:MRK) Offset The Coming Keytruda Patent Cliff? - Kalkine MediaKalkine Media · Thu, 06 Aug 2026 19:29:00 GMTMerck is pharma’s most patent-exposed company. Now it’s reinventing itself. - Pharma VoicePharma Voice · Wed, 05 Aug 2026 13:30:22 GMTMerck Is Fighting to Reduce the Blow From Keytruda's Patent Cliff With Smart R&D Strategy - MorningstarMorningstar · Tue, 04 Aug 2026 19:31:59 GMTEarnings Preview | Pfizer (PFE.US) and Merck (MRK.US) Announce Results on the Same Day: As Patent Cliff Meets New Growth Engines, the Pharmaceutical Industry Faces a Valuation Test - BitgetBitget · Tue, 04 Aug 2026 00:31:07 GMTMerck: Heading Into Q2 Earnings, The Keytruda Cliff Looks Increasingly Less Steep - Seeking AlphaSeeking Alpha · Fri, 31 Jul 2026 18:10:45 GMTMerck stock trades steady as Keytruda growth offsets patent cliff concerns - AD HOC NEWSAD HOC NEWS · Fri, 31 Jul 2026 07:00:00 GMTGenerics/Biosimilars Outlook: Major Patent Cliff Looms Large - DCAT Value Chain InsightsDCAT Value Chain Insights · Thu, 30 Jul 2026 19:12:00 GMT